Publications by authors named "Yamile Pena"
Background: NeuroEPO plus is a recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life due to its low sialic acid content. NeuroEPO plus prevents oxidative damage, neuroinflammation, apoptosis and cognitive deficit in an Alzheimer's disease (AD) models. The aim of this study was to assess efficacy and safety of neuroEPO plus.
View Article and Find Full Text PDFINTRODUCTION The availability of monoclonal antibodies in Cuba has facilitated development and application of innovative techniques (immunoscintigraphy and radioimmunotherapy) for cancer diagnosis and treatment. Objective Review immunoscintigraphy and radioimmunotherapy techniques and analyze their use in Cuba, based on the published literature. In this context, we describe the experience of Havana's Clinical Research Center with labeled monoclonal antibodies for cancer diagnosis and treatment during the period 1993-2013.
View Article and Find Full Text PDFArticle Synopsis
- Silent myocardial ischemia is common in type 2 diabetics, making traditional symptom-based diagnosis unreliable; research focuses on the link between blood lipid levels and ischemia.
- The study evaluated 220 asymptomatic type 2 diabetics in Havana over four years, using advanced imaging techniques (gSPECT) and confirmed findings through coronary angiography; classification trees identified specific lipid level cutoffs predictive of silent myocardial ischemia.
- Results showed that 29.1% had silent ischemia, with significant differences in lipid profiles: gSPECT-positive patients had higher total cholesterol, LDL, and triglycerides, while HDL was notably lower; men exhibited a higher prevalence of ischemia compared to women.
Radioimmunotherapy (RIT) may improve the management of malignant gliomas. A Phase I clinical trial was performed to evaluate, for the first time, the toxicity and clinical effect of an intracavitary administration of a single dose of Nimotuzumab (h-R3) labeled wit (188)Re. Nimotuzumab is a humanized monoclonal antibody directed against epidermal growth factor receptors.
View Article and Find Full Text PDFObjective: To evaluate the biodistribution, internal radiation dosimetry and safety of the 188Re-labelled humanized monoclonal antibody nimotuzumab in the locoregional treatment of malignant gliomas.
Methods: Single doses of 370 or 555 MBq of 188Re-labelled nimotuzumab were locoregionally administered to nine patients with recurrent high-grade gliomas, according to an approved dose-escalation study. SPECT, planar scintigraphy and magnetic resonance images were combined for dosimetric and pharmacokinetic studies.